Insights

Market Need Ophirex addresses a critical global health need by developing an affordable, easy-to-use oral snakebite treatment that can be administered immediately in the field, representing a significant opportunity to partner with healthcare providers and organizations in regions with high snakebite incidence.

Strategic Funding With $37 million raised in seed and Series B funding, Ophirex demonstrates strong investor confidence, indicating potential for future funding rounds or collaborations to accelerate product development and commercialization efforts.

Regulatory Progress Currently in human clinical trials, the company's ongoing development stage offers opportunities to engage with regulatory agencies and key opinion leaders to facilitate expedited approvals and market entry in targeted regions.

Technology Edge Ophirex leverages innovative biotech platforms and a broad-spectrum approach targeting the most common lethal components of venom, creating opportunities to license or co-develop additional treatments for related toxin-related health emergencies.

Market Expansion Given the global prevalence of venomous snakes and the unmet need for field-appropriate treatments in underserved areas, there is a significant sales opportunity to partner with governments, NGOs, and healthcare providers to distribute the treatment worldwide.

Ophirex, Inc. Tech Stack

Ophirex, Inc. uses 8 technology products and services including Varnish, Squarespace Commerce, Google Fonts API, and more. Explore Ophirex, Inc.'s tech stack below.

  • Varnish
    Caching
  • Squarespace Commerce
    E-commerce
  • Google Fonts API
    Font Scripts
  • Stimulus
    Javascript Frameworks
  • Choices
    Javascript Libraries
  • Webflow
    Page Builders
  • Lua
    Programming Languages
  • HSTS
    Security

Ophirex, Inc.'s Email Address Formats

Ophirex, Inc. uses at least 1 format(s):
Ophirex, Inc. Email FormatsExamplePercentage
First@ophirex.comJohn@ophirex.com
50%
First@ophirex.comJohn@ophirex.com
50%

Frequently Asked Questions

What is Ophirex, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Ophirex, Inc.'s official website is ophirex.com and has social profiles on LinkedInCrunchbase.

What is Ophirex, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Ophirex, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Ophirex, Inc. have currently?

Minus sign iconPlus sign icon
As of December 2025, Ophirex, Inc. has approximately 24 employees across 1 continents, including North America. Key team members include Chief Scientific Officer: L. B.Chief Medical Officer: T. P.Senior Vice President Regulatory Affairs: J. H.. Explore Ophirex, Inc.'s employee directory with LeadIQ.

What industry does Ophirex, Inc. belong to?

Minus sign iconPlus sign icon
Ophirex, Inc. operates in the Biotechnology Research industry.

What technology does Ophirex, Inc. use?

Minus sign iconPlus sign icon
Ophirex, Inc.'s tech stack includes VarnishSquarespace CommerceGoogle Fonts APIStimulusChoicesWebflowLuaHSTS.

What is Ophirex, Inc.'s email format?

Minus sign iconPlus sign icon
Ophirex, Inc.'s email format typically follows the pattern of First@ophirex.com. Find more Ophirex, Inc. email formats with LeadIQ.

How much funding has Ophirex, Inc. raised to date?

Minus sign iconPlus sign icon
As of December 2025, Ophirex, Inc. has raised $37M in funding. The last funding round occurred on Jan 05, 2023 for $37M.

When was Ophirex, Inc. founded?

Minus sign iconPlus sign icon
Ophirex, Inc. was founded in 2015.

Ophirex, Inc.

Biotechnology ResearchCalifornia, United States11-50 Employees

Ophirex, Inc., a Public Benefit Corp. focused on treatments for acute, life-threatening illnesses, is modernizing the treatment of snakebite victims by developing an affordable, accessible, oral treatment for immediate use anywhere a snake’s bite occurs.

Approximately 80% of the world’s population lives in close proximity to at least one venomous snake species and more than 500,000 people are killed or maimed by snakes each year worldwide.[1][2] Field treatments could help save hundreds of thousands of lives and limbs annually and provide enormous savings in healthcare costs.[2][3]

Ophirex is developing a “time of bite” oral snakebite treatment that blocks the most commonly lethal component of snake venom—present in 95% of the world’s venomous snakes.[4] This antidote—now in human clinical trials—can be administered immediately in the field or in the hospital to effectively stop the venom’s devastating assault.[5][6][7]

1. Vulnerability to snakebite envenoming: a global mapping of hotspots. www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31224-8/fulltext
2. Strategy for a globally coordinated response to a priority neglected tropical disease: Snakebite envenoming. https://doi.org/10.1371/journal.pntd.0007059
3. Snakebite: An Exploratory Cost-Effectiveness Analysis of Adjunct Treatment Strategies. www.ajtmh.org/view/journals/tpmd/99/2/article-p404.xml
4. A Review and Database of Snake Venom Proteomes. https://pubmed.ncbi.nlm.nih.gov/28927001/
5. Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. https://pubmed.ncbi.nlm.nih.gov/27571102/
6. Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms. www.ncbi.nlm.nih.gov/pmc/articles/PMC7076770/
7. Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite (BRAVO).
https://clinicaltrials.gov/ct2/show/NCT04996264

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
11-50

Section iconFunding & Financials

  • $37M

    Ophirex, Inc. has raised a total of $37M of funding over 2 rounds. Their latest funding round was raised on Jan 05, 2023 in the amount of $37M.

  • $10M$25M

    Ophirex, Inc.'s revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $37M

    Ophirex, Inc. has raised a total of $37M of funding over 2 rounds. Their latest funding round was raised on Jan 05, 2023 in the amount of $37M.

  • $10M$25M

    Ophirex, Inc.'s revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.